Patents by Inventor Yongxin Lai

Yongxin Lai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NITROTHIAZOLE DERIVATIVE AND APPLICATION THEREOF
    Publication number: 20240300910
    Abstract: A compound represented by formula (I) is effective in inhibiting the growth of Clostridium difficile. Compared with nitazoxanide and other antibiotics, the compound also has significantly less influence on intestinal probiotics and lower toxic side effects while significantly inhibiting the activity of Clostridium difficile, and the disease is not easy to relapse after the drug is stopped.
    Type: Application
    Filed: November 22, 2021
    Publication date: September 12, 2024
    Inventors: Bing GUANG, Tai YANG, Renhan DONG, Jin LIU, Wei ZHAN, Chuanjun QIN, Jian XIE, Sheng HUANG, Xiangyang PENG, Yongxin LAI, Qing XU, Jian PENG
  • RECEPTOR-INTERACTING PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF
    Publication number: 20240270732
    Abstract: A compound as a receptor-interacting protein (RIP) inhibitor, a preparation method therefor, and a use thereof, which relate to the field of chemical medicines, are provided. The compound is a compound as represented by formula (I), or a salt thereof, or a stereoisomer thereof, or a solvate thereof, or a prodrug thereof. The compound has good inhibitory activity on humanized RIP1 kinase, and can be used for preparing drugs for resisting inflammation, resisting tumors and the like.
    Type: Application
    Filed: May 17, 2022
    Publication date: August 15, 2024
    Inventors: Bing GUANG, Tai YANG, Renhan DONG, Chuanjun QIN, Jian XIE, Jian PENG, Sheng HUANG, Jin LIU, Wei ZHAN, Yongxin LAI, Xiangyang PENG, Qing XU, Yisheng ZENG, Xiaojun HU
  • COMPOUND FOR PREVENTING AND TREATING LIVER DISEASES AND PHARMACEUTICAL USE THEREOF
    Publication number: 20230330109
    Abstract: A compound as represented by formula I-1, or a pharmaceutically acceptable salt, a stereoisomer, or a solvate thereof are effective in reducing ALT, AST and ALP as well as helpful in treating hepatic pathological injuries (e.g. hepatocyte steatosis). The compound has wide application prospects in the preparation of a drug for preventing and/or treating liver diseases such as fatty liver, hepatic fibrosis and liver cirrhosis.
    Type: Application
    Filed: September 17, 2021
    Publication date: October 19, 2023
    Inventors: Bing GUANG, Tai YANG, Renhan DONG, Wei ZHAN, Jin LIU, Chuanjun QIN, Jian XIE, Sheng HUANG, Xiangyang PENG, Yongxin LAI, Qing XU, Jian PENG, Yisheng ZENG, Xiaojun HU
  • COMPOUND WITH ANTI-SPORE ACTIVITY AND PHARMACEUTICAL COMPOSITION THEREOF
    Publication number: 20230135729
    Abstract: The present disclosure provides a compound represented by formula (I), or a salt or a stereoisomer thereof. The compound is capable of effectively inhibiting germination of Clostridium difficile spores with a significant bacteriostatic activity. The compound has an excellent prospect for use in preparation of a drug for preventing and/or treating a C. difficile-caused infectious disease, recurrence of the C. difficile-caused infectious disease, or a complication of the C. difficile-caused infectious disease.
    Type: Application
    Filed: February 7, 2020
    Publication date: May 4, 2023
    Applicant: CHENGDU BIOBEL COMPANY LIMITED
    Inventors: Bing Guang, Tai Yang, Renhan Dong, Jin Liu, Jian Xie, Chuanjun Qin, Sheng Huang, Xiangyang Peng, Qing Xu, Yongxin Lai, Wei Zhan, Jian Peng, Xiaohui Wang